Our company comprises both cutting-edge and well-established medications, holding prominent positions in the fields of Antibiotics and Analgesics. Within our Pharmaceuticals Market R&D organization, we lead the way in research and development across various core areas, including respiratory health, HIV and infectious diseases, oncology, immuno-inflammation, antipsychotics, dental care, and rare diseases.
BY Parolin Pharmaceutical
Our Pharmaceuticals division is dedicated to the research, development, and production of medications aimed at addressing a wide spectrum of both prevalent acute and chronic diseases worldwide.
| # | Regions | USD (in million) |
|---|---|---|
| 1 | Middle East Asia | 2.8 |
| 2 | South East Asia | 1.6 |
| 3 | Central America | 1.1 |
The global pharmaceuticals market is extensive, with significant growth occurring in recent years, particularly in emerging markets and the regions of Middle East-Asia and South East Asia.
This trend of rising demand is anticipated to persist, driven by the world's growing population, the increasing prosperity of emerging market economies, and global shifts in lifestyles that impact long-term health.
Our Pharmaceuticals division generates value through the research and production of groundbreaking products, with the goal of ensuring widespread access to these innovations across countries, regardless of their income levels or development status.
Although we maintain a robust presence in developing markets like the Middle East-Asia, we are bolstering our investments in emerging markets, encompassing Central America and Euro-Asian nations, where we recognize substantial growth opportunities.
Our product portfolio comprises both innovative and well-established medications. For over seven years, we have been a prominent exporter of antibiotics, analgesics, antipsychotics, and local anesthetics. We also have a range of mature products. In recent times, we have expanded and strengthened our local anesthetic offerings, introducing new dental products such as Lidocaine Dental carpoules, Articaine, Mepavacaine, Bupivacaine in Dental Glass carpoules, and Lidocaine-flavored spray for dental procedures.
Furthermore, beyond local anesthetics, our portfolio includes various other innovative pharmaceutical products designed to address conditions like neuropathic pain, cardiovascular disorders, and dermal diseases.
Additionally, we maintain an Established Products Portfolio (EPP) that encompasses mature medicines in categories such as anti-infectives, allergy, central nervous system, dermatology, respiratory, and urology. These products play a vital role in our Emerging Markets business, where the ZYMETH brand serves as a significant distinguishing factor.
